MAPT and Alzheimer disease: In our study, as compared with the SCI/MCI group, the AD group was older and had deteriorated levels of hypertension frequency, systolic blood pressure, MAP, APOEɛ4 allele distribution, and CSF AD biomarkers (Aβ1–42, P-tau, and T-tau).